|Description||HDAC-IN-2, a selective HDAC inhibitor, has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma. IC50: 4 nM and 76 nM for|
|Synonyms||HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat|
|Solubility||DMSO: ≥ 30 mg/mL|
|Application||HDAC-IN-2 is a selective HDAC inhibitor that has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Acetylon Pharmaceuticals|
Mocetinostat is a rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activi...
Sodium butyrate is the sodium salt of butyric acid, used in the culture of mammalian cells.
Quisinostat, also known as JNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potent...
Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects.
Scriptaid is an inhibitor of HDAC. It shows a greater effect on acetylated H4 than H3.
Trichostatin A, also known as TSA, is a HDAC inhibitor. TSA inhibits the eukaryotic cell cycle during the beginning of the growth stage. TSA can be used to alte...
PCI-34051 is a potent, histone deacetylase 8 (HDAC8)-specific inhibitor with >200-fold selectivity over the other HDAC isoforms. PCI-34051 induces caspase-depen...
Remodelin, via inhibition of NAT10, mediates nuclear shape rescue of LMNA depleted cells by microtubule reorganization, and improves nuclear shape and fitness o...
ST7612AA1 is a potent Histone deacetylase (HDCA) inhibitor. It showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor...
Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM ...
Abexinostat, also known as PCI-24781 or CRA-024781, is novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antine...
Rocilinostat, previously known as ACY-1215, is an orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activi...
Valproic acid sodium salt (Sodium valpro
Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention o...
Oxamflatin, also known as Metacept-3, an aromatic sulfonamide derivative, is a cell-permeable, potent HDAC inhibitor (IC50= 15.7 nM) with antitumor effect.
Belinostat is a novel pan-HDAC inhibitor with IC50 of 27 nM, with activity demonstrated in cisplatin-resistant tumors. It inhibits the growth of tumor cells wit...
Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately...
Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits ...
Tasquinimod is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease b...
CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respecti...